Global Information
회사소개 | 문의

심방세동(AF) : 주요 19개국 시장 예측

Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 08월 상품 코드 342571
페이지 정보 영문 76 Pages
가격
US $ 5,800 ₩ 6,658,400 PDF by E-mail (Single User License)
US $ 8,700 ₩ 9,987,600 PDF by E-mail (Site License)
US $ 10,400 ₩ 11,939,200 PDF by E-mail (Global License)


심방세동(AF) : 주요 19개국 시장 예측 Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2018-2028
발행일: 2018년 08월 페이지 정보 : 영문 76 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

심방세동(AF)은 상실성 부정맥의 가장 일반적인 유형입니다. 비정상적인 전기신호가 심방에 보내지면 심방세동(AF)이 발생합니다.

주요 19개국 시장(미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 러시아, 터키, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나)의 심방세동(AF: Atrial Fibrillation) 현재 환자수(성별, 연령 코호트별)에 대해 조사 분석했으며, 현재 유병률, 질환 개요, 위험인자, 질환의 진단과 예후, 주요 증상과 합병증 등의 정보를 정리하여 전해드립니다.

도표

서론

병인

위험인자와 예방

질환의 진단

변이 : 지역/민족별

질환의 예후와 임상 경과

질환에 관련된 주요 합병증/특징

환자수 정량화 방법

심방세동(AF) 최대 환자수

심방세동(AF) 환자의 특징

  • 중재적 치료
  • 심방세동(AF) 환자의 동반질병

약어

기타 서비스 및 솔루션

  • 보고서 및 출판물
  • 온라인 역학 데이터베이스
  • 온라인 약가 데이터베이스

참고 문헌

부록

LSH 18.08.01

영문목차

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atrial Fibrillation in 19 Major Markets

Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.

This report provides the current prevalent population for AF across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AF include:

Hypertension

CHF/CAD and other structural cardiac diseases

Diabetes

Mitral stenosis / other valvular disorders

COPD

Stroke

Rheumatic heart disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global AF market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of AF and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of AF patients.

Identification of AF patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of AF patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • ADDITIONAL DATA AVAILABLE ON REQUEST
  • TOP-LINE PREVALENCE FOR ATRIAL FIBRILLATION
  • FEATURES OF ATRIAL FIBRILLATION PATIENTS
  • THERAPEUTIC INTERVENTIONS
  • COMORBIDITIES OF ATRIAL FIBRILLATION PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of AF, total (000s)
  • Table 2. Prevalence of AF, males (000s)
  • Table 3. Prevalence of AF, females (000s)
  • Table 4. Patients with AF by classification according to duration of episode, total (000s)
  • Table 5. Patients with new-onset AF, total (000s)
  • Table 6. Patients with valvular vs. non-valvular AF, total (000s)
  • Table 7. AF patients with a history of catheter ablation, total (000s)
  • Table 8. AF patients on anti-arrhythmic therapy, total (000s)
  • Table 9. AF patients with an established rhythm control strategy, total (000s)
  • Table 10. AF patients with a pacemaker / ICD implant, total (000s)
  • Table 11. AF patients on vitamin K antagonist therapy, total (000s)
  • Table 12. AF patients on anti-platelet therapy, total (000s)
  • Table 13. AF patients with a history of stroke, total (000s)
  • Table 14. Patients with atrial fibrillation by 5-year incidence of stroke event, total (000s)
  • Table 15. AF patients with coronary artery disease, total (000s)
  • Table 16. AF patients with chronic heart failure, total (000s)
  • Table 17. AF patients with peripheral artery disease, total (000s)
  • Table 18. AF patients with a history of myocardial infarction, total (000s)
  • Table 19. AF patients with left ventricular hypertrophy, total (000s)
  • Table 20. AF patients with diabetes, total (000s)
  • Table 21. AF patients with hypertension, total (000s)
  • Table 22. AF patients with COPD, total (000s)
  • Table 23. AF patients with rheumatic heart disease, total (000s)
  • Table 24. AF patients with valvular artery disease, total (000s)
  • Table 25. Abbreviations and acronyms used in the report
  • Table 26. USA prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 27. USA prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 28. Canada prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 29. Canada prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 30. France prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 31. France prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 32. Germany prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 33. Germany prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 34. Italy prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 35. Italy prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 36. Spain prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 37. Spain prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 38. UK prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 39. UK prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 40. Poland prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 41. Poland prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 42. Netherlands prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 43. Netherlands prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 44. Russia prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 45. Russia prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 46. Turkey prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 47. Turkey prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 48. Japan prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 49. Japan prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 50. China prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 51. China prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 52. South Korea prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 53. South Korea prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 54. India prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 55. India prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 56. Australia prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 57. Australia prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 58. Brazil prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 59. Brazil prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 60. Mexico prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 61. Mexico prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
  • Table 62. Argentina prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
  • Table 63. Argentina prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research